MiNK Therapeutics (INKT) Long-Term Debt Issuances (2024 - 2026)

MiNK Therapeutics (INKT) posted Long-Term Debt Issuances of $5.0 million for Q1 2026, little changed sequentially from $5.0 million in Q1 2024.

MiNK Therapeutics (INKT) Long-Term Debt Issuances (2024 - 2026) Analysis & Trends

MiNK Therapeutics has reported Long-Term Debt Issuances for 2 years, with the latest figure at $5.0 million in Q1 2026.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (changed N/A YoY) and the FY2024 annual result came in at $5.0 million, changed N/A from the prior year.
Long-Term Debt Issuances was little changed at $5.0 million in Q1 2026 per INKT's latest filing, from $5.0 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $5.0 million in Q1 2024 and troughed at $5.0 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	MiNK Therapeutics	60.53 Mn	60.53 Mn	-	-

Download Data